Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.9K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.9K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

613
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
613
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.9K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.9K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

364
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
364
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

365
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
365
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

1.2K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mitral annular calcification, coronary artery calcification, and risk of incident atrial fibrillation in the multi-ethnic study of atherosclerosis (MESA).

Journal of cardiovascular computed tomography·2026
Same author

Long-Term Associations of Subconcussive Blast Exposure With Brain Function and Structure.

The Journal of head trauma rehabilitation·2026
Same author

Circulating gut microbial metabolites and risk of coronary heart disease: A prospective multi-stage metabolomics study.

PLoS medicine·2026
Same author

Circulating Ketone Bodies and Incident Cardiovascular Outcomes and Mortality: Insights From the UK Biobank.

Journal of the American Heart Association·2026
Same author

Synthetic Contrast-Free LGE in Acute MI: Assessing the Promise and Boundaries of Diffusion-Based Modeling.

Circulation. Cardiovascular imaging·2026
Same author

Cost-Effectiveness of Coronary Artery Calcium Scoring for Cardiovascular Disease Prevention in Diabetes: An Analysis From MESA.

Journal of the American Heart Association·2025

Related Experiment Video

Updated: Apr 17, 2026

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.2K

Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection

Runyawan Chotenimitkhun1, Ralph D'Agostino2, Julia A Lawrence3

  • 1Department of Cardiology, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.

The Canadian Journal of Cardiology
|February 10, 2015
PubMed
Summary

Statin therapy may protect against left ventricular ejection fraction (LVEF) decline during anthracycline chemotherapy. Patients on statins showed preserved LVEF, while those not on statins experienced significant declines, suggesting a cardioprotective effect.

More Related Videos

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.8K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

Related Experiment Videos

Last Updated: Apr 17, 2026

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.2K
Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.8K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

Area of Science:

  • Cardiology
  • Oncology
  • Pharmacology

Background:

  • Anthracycline-based chemotherapy (Anth-bC) is associated with declines in left ventricular ejection fraction (LVEF).
  • Statin therapy has been linked to reduced heart failure risk in breast cancer survivors.

Purpose of the Study:

  • To evaluate if statins, used for cardiovascular disease prevention, can mitigate LVEF decline during Anth-bC.

Main Methods:

  • 51 participants (cancer patients) underwent cardiovascular magnetic resonance imaging (CMRI) for LVEF measurement before and 6 months after Anth-bC.
  • 14 participants received statins; 37 did not. MR image analysts were blinded.

Main Results:

  • Participants on statins showed no significant LVEF decline (P=0.15), maintaining LVEF around 54%.
  • Participants not on statins experienced a significant LVEF decrease from 57.5% to 52.4% (P=0.0003).
  • Multivariable analysis confirmed statin use was associated with preserved LVEF (P=0.03) compared to non-users.

Conclusions:

  • Statin therapy may reduce LVEF deterioration in patients receiving Anth-bC.
  • Further large-scale studies are needed to confirm statins' protective role against LVEF decline in Anth-bC patients.